IPMK and metabolic dysfunction-associated steatohepatitis: Further studies are needed to understand how IPMK mediates changes in hepatic lipid metabolism, inflammation, and fibrosis in NASH, and how TRF modulates the levels of IPMK in the liver to prevent the development of NASH.